Issuer: Novo Nordisk Finance (Netherlands) B.V.

Guarantor: Novo Nordisk A/S

Amount: EUR 650 million

Coupon: 0%

Issue date: 4 June 2021

Maturity: 4 June 2024

ISIN: XS2348030268

 

Issuer: Novo Nordisk Finance (Netherlands) B.V.

Guarantor: Novo Nordisk A/S

Amount: EUR 650 million

Coupon: 0.125%

Issue date: 4 June 2021

Maturity: 4 June 2028

ISIN: XS2348030425

 

Issuer: Novo Nordisk Finance (Netherlands) B.V.

Guarantor: Novo Nordisk A/S

Amount: EUR 500 million

Coupon: 0.75%

Issue date: 31 March 2022

Maturity: 31 March 2025

ISIN: XS2441244535

 

Issuer: Novo Nordisk Finance (Netherlands) B.V.

Guarantor: Novo Nordisk A/S

Amount: EUR 500 million

Coupon: 1.125%

Issue date: 31 March 2022

Maturity: 30 September 2027

ISIN: XS2449330179

 

Issuer: Novo Nordisk Finance (Netherlands) B.V.

Guarantor: Novo Nordisk A/S

Amount: EUR 500 million

Coupon: 1.375%

Issue date: 31 March 2022

Maturity: 31 March 2030

ISIN: XS2441247041

Moody's Investors Service
Long-term: A1
Outlook: Stable

S&P Global Ratings
Long-term: AA-
Outlook: Stable

On 20 May 2021, Novo Nordisk A/S established a Euro Medium Term Note programme (the “Programme”) listed on the Euronext Dublin Regulated Market of the Irish Stock Exchange. On 8 June 2022, Novo Nordisk A/S updated the Euro Medium Term Note programme (the “Programme”) listed on the Euronext Dublin Regulated Market of the Irish Stock Exchange.

Base Prospectus

Investors

Share price

{{priceData.date}} {{priceData.time}}

{{priceData.currentPrice}} {{priceData.currency}}
Go to stock watch {{priceData.change}} {{priceData.currency}}

Annual Report

Cover page of the Novo Nordisk Annual Report 2021

Annual Report 2021

Download Annual Report